In recent years, with the change of living environment and dietary habits, the incidence of precocious puberty is rising, and the incidence of girls is obviously higher than that of boys. Gonadotropin releasing hormone analogue (GnRHa) is currently the main treatment measure of central precocious puberty (CPP). Most studies focus on GnRHa’s impact on final height. However, there is less research about its effect on CPP girls’ ovarian reserve function. The outcome of ovarian reserve function can help predict the reproductive function of CPP children early, which will eliminate the anxieties of the children and parents, and improve the compliance of the treatment.